Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease.
about
Octyl gallate markedly promotes anti-amyloidogenic processing of APP through estrogen receptor-mediated ADAM10 activationProtein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitusRivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neuronsCognitive Impairments Induced by Concussive Mild Traumatic Brain Injury in Mouse Are Ameliorated by Treatment with Phenserine via Multiple Non-Cholinergic and Cholinergic MechanismsSelective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodentEfavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND).Investigation of the noncovalent interactions between anti-amyloid agents and amyloid beta peptides by ESI-MS.Geranylgeranyl pyrophosphate stimulates gamma-secretase to increase the generation of Abeta and APP-CTFgamma.Value in development of a TAPIR-like mouse monoclonal antibody to Abeta.Linkage disequilibrium and association of MAPT H1 in Parkinson diseaseBeta-secretase: structure, function, and evolution.GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease.Short-term administration of omega 3 fatty acids from fish oil results in increased transthyretin transcription in old rat hippocampus.Structure of A beta(25-35) peptide in different environmentsFrontiers in the pathogenesis of Alzheimer's disease.Neurotrophic and neuroprotective actions of (-)- and (+)-phenserine, candidate drugs for Alzheimer's disease.Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysisTargets for AD treatment: conflicting messages from γ-secretase inhibitorsAmyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivoPeripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseasesMemantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid beta (A beta) peptide in the human neuroblastoma cellsRestraint stress and repeated corticotrophin-releasing factor receptor activation in the amygdala both increase amyloid-β precursor protein and amyloid-β peptide but have divergent effects on brain-derived neurotrophic factor and pre-synaptic proteiDifferential accumulation of secreted AbetaPP metabolites in ocular fluidsA novel study on amyloid β peptide 40, 42 and 40/42 ratio in Saudi autistics.Tumor necrosis factor-α synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's diseasePosiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disordersEVALUATION OF HOW CIGARETTE SMOKE IS A DIRECT RISK FACTOR FOR ALZHEIMER'S DISEASE.Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease.Molecular Docking and In Silico ADMET Study Reveals Acylguanidine 7a as a Potential Inhibitor of β-SecretasePerilla frutescens var. japonica and rosmarinic acid improve amyloid-β25-35 induced impairment of cognition and memory functionExendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in miceBiochemical studies in Normal Pressure Hydrocephalus (NPH) patients: change in CSF levels of amyloid precursor protein (APP), amyloid-beta (Aβ) peptide and phospho-tauBlueberry opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activation protein kinasePigment epithelium-derived factor maintains retinal pigment epithelium function by inhibiting vascular endothelial growth factor-R2 signaling through gamma-secretaseMemantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice.Phenserine efficacy in Alzheimer's disease.Intracellular trafficking of the β-secretase and processing of amyloid precursor protein.Metallostasis and amyloid β-degrading enzymes.Chemical biology based on target-selective degradation of proteins and carbohydrates using light-activatable organic molecules.
P2860
Q21132562-781BBCA9-F86A-4E11-9691-4CBFF4987DDBQ28397425-85582DBA-6E7F-47FA-89E2-6A319D226A20Q28479242-2774A568-4ACB-4057-8902-936C52FF35DEQ28552599-4132A858-B240-4BD2-8C4F-D33529D828B8Q28578059-E8DB86DA-EDE3-4B54-80DA-31CE989563A9Q31159582-B03302DC-39E7-4833-9883-B4574A3547FAQ33617203-A52EB8AD-8FF6-4A1C-A9C6-4481544170EBQ33811355-CB2E3212-3DE1-4423-9E53-B84411BD2E23Q33824597-CE80167E-0788-4FFB-AC4B-CE6D1A737932Q33910188-251B229A-4EE3-4E8F-851B-18B71B788474Q34066765-10E78DD5-6B2C-427C-AB0E-D45AAA0AA567Q34167980-9B8380A4-DB6B-4535-96E8-203849B8AD42Q34175004-D9583B96-4BB4-41F9-83CB-5BC600BC6C7FQ34186350-A9C2528A-25A1-4FD9-80B7-AB886CF1C208Q34572020-BCC849F9-8FDB-4147-BC3E-49E86A9423A5Q34575780-914E226D-117A-4C2B-B935-9574B8E2B521Q34743671-C48AFE62-0FCE-44E6-93A6-272251E9C426Q34792043-0622B1BD-140B-4C43-8623-6464F7E887FBQ35023290-79D1A41A-0BD8-48EB-B024-D1123AD44AB9Q36023238-45903EE6-3531-4EF8-9914-5C3A1AA3F1EDQ36047013-4663688B-56A8-4CF8-A6DA-A3010B32DFD3Q36081631-821B73F3-5EA3-4780-AC05-DF20FA4A8A1DQ36097397-5B659274-5544-468E-9C20-4EAA128D6826Q36099067-80BCE2CB-52E3-4898-8185-C4D7D4CF2874Q36118204-B7E4F814-468F-4468-BC64-B3CD59172001Q36152393-520BE1C3-2F2D-4C0D-A4AF-8151EF32FE9FQ36166654-D60B2D40-A904-4F84-A998-A8D0738D3613Q36241900-E9B72183-60F3-4CEC-98C1-16DBA8E65426Q36764094-198017D9-07F2-441D-981D-0CDF552580B0Q36828224-DAED7948-B679-420D-A58C-AC22C6A6A732Q36936827-2CE03EFF-AA49-472B-B8DF-893A9282C2CEQ37179909-09EA8A1E-5A84-449F-99EE-562006B263EFQ37269006-63F8E20B-255B-4A54-88AD-DE9D8F964CBDQ37362513-89DC246F-68FA-46FA-A89D-E4688242B619Q37431688-38ADB87C-6D85-41B2-9CEB-4D6A40DF0346Q37440780-BF27C952-8200-463C-AC57-B41C38C78FC8Q37510264-56B5C20E-9A9F-4BD9-AE2F-96CA9CA99B84Q37915426-2A1A929D-52FD-43C0-851D-BCDC459E23C3Q38029514-B2E52CB7-3E3B-41EA-B27E-073FEFE2198BQ38068131-553B377F-7D93-466C-9248-A5650C2DE8D4
P2860
Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Advances in the cellular and m ...... rotein in Alzheimer's disease.
@ast
Advances in the cellular and m ...... rotein in Alzheimer's disease.
@en
Advances in the cellular and m ...... rotein in Alzheimer's disease.
@nl
type
label
Advances in the cellular and m ...... rotein in Alzheimer's disease.
@ast
Advances in the cellular and m ...... rotein in Alzheimer's disease.
@en
Advances in the cellular and m ...... rotein in Alzheimer's disease.
@nl
prefLabel
Advances in the cellular and m ...... rotein in Alzheimer's disease.
@ast
Advances in the cellular and m ...... rotein in Alzheimer's disease.
@en
Advances in the cellular and m ...... rotein in Alzheimer's disease.
@nl
P2093
P356
P1476
Advances in the cellular and m ...... rotein in Alzheimer's disease.
@en
P2093
Debomoy K Lahiri
Kumar Sambamurti
Nigel H Greig
P2888
P356
10.1385/NMM:1:1:1
P577
2002-01-01T00:00:00Z
P6179
1015367988